A nationwide shortage of BCG vaccines is leaving Kenyan newborns vulnerable to TB, a disease with high prevalence, health ...

Health Non-Governmental Organisations Network (HENNET) has blamed low budgetary allocation for the recurring vaccine ...

With only seven members, iGEM Eindhoven forms a small but determined student team that aims to help shape the future of ...

JNJ's regulatory filing seeks the FDA's approval for TAR-200, a drug-device combination for treating certain bladder cancer ...

The push for the elimination of leprosy leads to a reduction of cases worldwide but might also have led to a premature perception that leprosy is no longer a public-health concern, with potential ...

An FDA application for TAR-200 to treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer is under real-time ...

There is consistent evidence that BCG protects against leprosy. However, the magnitude of such a protection varies greatly in different studies and is estimated to be approximately 41% (95% CI: 16 ...

This challenge is largely attributed to the government’s failure to properly project population growth. Approximately one ...

In vivo perturbations and single-cell RNA-seq reveal cell-type-specific STAT1-IFNg signaling in regulation of trained immunity in tissue-resident immune cells.

They were used on five patients, and four of them are now either in remission or cancer-free. Read more at straitstimes.com.

J&J acquired rights to TAR-200 when it bought privately-owned biotech Taris for an undisclosed sum in 2019, and has big sales ...